Disease Focus: Autoimmune Disorder

A Phase 1 Study of FT819 in Participants with Moderate to Severe Active Systemic Lupus Erythematosus

Therapeutic Candidate or Device iPSC-derived CD19 CAR T cell therapy Indication Systemic Lupus Erythematosus Therapeutic Mechanism Depletion of CD19+ B cells and plasmablasts Unmet Medical Need Potential for drug-free remission and reset of the immune system Project Objective Phase 1 trial completed Major Proposed Activities Site Activation and Patient Enrollment Clinical Trial Data Monitoring, Database […]